-- Significant step toward reimbursement for the only medical device approved in the U.S. for treatment of gait deficit due to multiple sclerosis (“MS”) --
-- Proceeds from recent stock issuances through the Company’s At-The-Market (“ATM”) program extends cash runway into the third quarter 2024 --
NEWTOWN, Pa., March 04, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Centers for Medicare & Medicaid Services (“CMS”) has assigned Healthcare Common Procedure Coding System (“HCPCS”) Level II codes A4593, “Neuromodulation stimulator system, adjunct to rehabilitation therapy regime” to describe the PoNS controller and A4594, “Neuromodulation stimulator system, adjunct to rehabilitation therapy regime, mouthpiece each” to describe the PoNS mouthpiece. The new HCPCS codes will be effective April 1, 2024.
“PoNS Therapy® is life-changing for people who suffer gait impairment due to MS and we’re pleased that CMS understood the benefits of this innovative treatment by establishing HCPCS codes for both the PoNS mouthpiece and controller. This marks a critical reimbursement and access milestone and provides Helius the ability to begin negotiating reimbursement with third-party payers using these unique HCPCS codes. We believe there is a reasonable likelihood that at the public meetings this summer CMS will determine a reimbursement amount for each of the PoNS controller and mouthpiece to take effect on October 1, 2024,” stated Helius’ President and Chief Executive Officer, Dane Andreeff.
“As we pursue widespread reimbursement for PoNS Therapy, we have continued to manage our cash burn. With the recently announced $1.5 million of net proceeds from the sale of shares of our common stock under our ATM program at an average share price of $9.17 per share, our cash runway has been extended into the third quarter of this year. Once we establish reimbursement for PoNS, we believe we will be able to expand reimbursement across third-party payers and have a pathway to positive cash flow as we continue to pursue authorization for stroke in the U.S.,” concluded Andreeff.
PoNS is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from MS and is to be used as an adjunct to a supervised therapeutic exercise program. The Company is also seeking marketing authorization under PoNS’s breakthrough designation for stroke in the United States, where over five million stroke survivors are affected by walking and balance disability. In Canada, PoNS is authorized to treat balance impairment due to MS, stroke and mild-to-moderate traumatic brain injury.
About Helius Medical Technologies, Inc.
Recent HSDT News
- Helius Medical Technologies, Inc. Announces Pricing of $6.4 Million Public Offering • GlobeNewswire Inc. • 05/07/2024 02:15:00 AM
- Helius Medical Technologies, Inc. Announces Preliminary CMS Payment Determination of Reimbursement for Portable Neuromodulation Stimulator (PoNS®) • GlobeNewswire Inc. • 05/06/2024 01:00:00 PM
- Helius Medical Technologies, Inc. Expands Stroke Clinical Program with Participation of Shepherd Center • GlobeNewswire Inc. • 04/24/2024 01:05:00 PM
- Helius Medical Technologies, Inc. Announces Partnership with Lovell® Government Services to Expand Reach of PoNS Therapy™ • GlobeNewswire Inc. • 04/03/2024 11:05:00 AM
- Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/28/2024 08:05:00 PM
- Helius Medical Technologies, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024 • GlobeNewswire Inc. • 03/15/2024 11:05:00 AM
- Helius Medical Technologies, Inc. Initiates Open-Label Study for Registrational Program in Stroke • GlobeNewswire Inc. • 03/12/2024 12:59:22 PM
- Helius Medical Technologies, Inc. to Present at the 36th Annual ROTH Conference • GlobeNewswire Inc. • 03/07/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 12:30:51 PM
- Helius Medical Technologies, Inc. Secures HCPCS Codes for Portable Neuromodulation Stimulator (PoNS®) Mouthpiece and Controller • GlobeNewswire Inc. • 03/04/2024 12:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 12:09:07 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 09:15:49 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 03:22:13 PM
- Helius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients • GlobeNewswire Inc. • 02/06/2024 12:00:00 PM
- Helius Booth and Special Event at APTA Combined Sections Meeting Will Highlight Physical Therapists’ Ability to Customize PoNS Therapy® to Improve Gait in People with MS • GlobeNewswire Inc. • 02/05/2024 12:05:00 PM
- Helius Medical Technologies, Inc. Announces Further Expansion of Stroke Clinical Program with the Addition of Brooks Rehabilitation Hospital • GlobeNewswire Inc. • 01/11/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 02:00:31 PM
- Helius Medical Technologies to Present at NobleCon19 Annual Conference • GlobeNewswire Inc. • 11/30/2023 12:47:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:15:22 PM
- Helius Medical Technologies, Inc. Reports Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/09/2023 09:05:00 PM
- Helius Medical Technologies, Inc. Announces Study Results Demonstrating That PoNS Therapy™ Helps Patients with Traumatic Brain Injury Return to Work • GlobeNewswire Inc. • 11/06/2023 12:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/02/2023 09:15:18 PM
- Helius Medical Technologies, Inc. to Release Third Quarter 2023 Financial Results on November 9, 2023; Announces Extended Cash Runway into Q2 2024 • GlobeNewswire Inc. • 11/02/2023 09:05:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM